drugset / Trial / NCT00537602
Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
RandomizedCrossoverQuadruple-blindTreatment
Summary
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.
Timeline
- Start
- 2007-11
- Primary completion
- 2008-02
- Completion
- 2008-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Miglustat | Small molecule | 200 mg | Oral |